Table 5.
The monthly changes of MRS metabolites in different groups of patients ╥
| Cerebellar hemispheres | Vermis | |||||
|---|---|---|---|---|---|---|
| NAA/Cr | Cho/Cr | NAA/Cho | NAA/Cr | Cho/Cr | NAA/Cho | |
| p # | 0.471 | 0.168 | 0.261 | 0.693 | 0.269 | 0.273 |
| SCA2 | 0.09 ± 0.17 | 0.13 ± 0.14 | −0.08 ± 0.28 | −0.25 ± 0.53 | −0.18 ± 0.23 | −0.08 ± 0.68 |
| SCA3 | −0.04 ± 0.22 | −0.04 ± 0.26 | 0.01 ± 0.61 | −0.07 ± 0.20 | 0.05 ± 0.21 | −0.22 ± 0.37 |
| SCA6 | 0.06 ± 0.22 | −0.11 ± 0.16 | 0.27 ± 0.44 | −0.18 ± 0.13 | −0.16 ± 0.16 | 0.00 ± 0.45 |
| MSA-C | 0.14 ± 0.59 | 0.02 ± 0.37 | 0.33 ± 1.14 | 0.03 ± 0.32 | −0.14 ± 0.36 | 0.51 ± 0.86 |
SCA2: Spinocerebellar ataxia type 2; SCA3: Spinocerebellar ataxia type 3; SCA6: Spinocerebellar ataxia type 6; MSA-C: Multiple system atrophy- cerebellar type.
╥Data are presented as 100X MRS ratios.
#Kruskal-Wallis test.